Tag: immunotherapy

1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...

Imfinzi Combo Shows Promise in Early Gastric Cancer At the American Society of Clinical Oncology meeting earlier this week, investigators ...

1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade ...

1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...

1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...

1. In this phase two dose-finding study in children with achondroplasia, daily oral Infigratinib did not lead to any grade ...

1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher ...

1. Intracranial objective response rate was 51% with ipilimumab plus nivolumab and 20% with nivolumab alone. 2. Treatment-related grade 3 ...

1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related ...

1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade ...